End-of-day quote
Korea S.E.
23:00:00 13/05/2024 BST
|
5-day change
|
1st Jan Change
|
8,250
KRW
|
+1.85%
|
|
+3.00%
|
-22.90%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
154,210
|
116,133
|
160,165
|
211,563
|
150,625
|
255,824
|
Enterprise Value (EV)
1 |
209,885
|
169,708
|
215,786
|
244,524
|
166,233
|
266,434
|
P/E ratio
|
-15.8
x
|
-8.45
x
|
-7.88
x
|
-27.5
x
|
22.3
x
|
-16.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.11
x
|
0.85
x
|
1.23
x
|
1.51
x
|
0.91
x
|
1.86
x
|
EV / Revenue
|
1.52
x
|
1.25
x
|
1.66
x
|
1.74
x
|
1.01
x
|
1.93
x
|
EV / EBITDA
|
-225
x
|
68.8
x
|
-3,512
x
|
73.1
x
|
9.02
x
|
195
x
|
EV / FCF
|
-28.7
x
|
57.8
x
|
-18.7
x
|
-313
x
|
12.4
x
|
46.5
x
|
FCF Yield
|
-3.48%
|
1.73%
|
-5.36%
|
-0.32%
|
8.1%
|
2.15%
|
Price to Book
|
1.78
x
|
1.55
x
|
2.1
x
|
2.49
x
|
1.57
x
|
3.39
x
|
Nbr of stocks (in thousands)
|
19,038
|
19,038
|
20,774
|
23,351
|
23,909
|
23,909
|
Reference price
2 |
8,100
|
6,100
|
7,710
|
9,060
|
6,300
|
10,700
|
Announcement Date
|
21/03/19
|
18/03/20
|
17/03/21
|
18/03/22
|
23/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
138,400
|
136,124
|
130,032
|
140,318
|
165,206
|
137,878
|
EBITDA
1 |
-930.9
|
2,467
|
-61.44
|
3,344
|
18,423
|
1,368
|
EBIT
1 |
-5,856
|
-3,856
|
-5,877
|
-2,938
|
11,717
|
-4,578
|
Operating Margin
|
-4.23%
|
-2.83%
|
-4.52%
|
-2.09%
|
7.09%
|
-3.32%
|
Earnings before Tax (EBT)
1 |
-6,848
|
-13,048
|
-22,738
|
-7,687
|
-37.6
|
-15,715
|
Net income
1 |
-9,061
|
-13,739
|
-19,458
|
-7,318
|
6,752
|
-15,588
|
Net margin
|
-6.55%
|
-10.09%
|
-14.96%
|
-5.22%
|
4.09%
|
-11.31%
|
EPS
2 |
-513.9
|
-722.0
|
-978.0
|
-329.3
|
283.0
|
-652.0
|
Free Cash Flow
1 |
-7,302
|
2,934
|
-11,563
|
-780.8
|
13,460
|
5,724
|
FCF margin
|
-5.28%
|
2.16%
|
-8.89%
|
-0.56%
|
8.15%
|
4.15%
|
FCF Conversion (EBITDA)
|
-
|
118.94%
|
-
|
-
|
73.06%
|
418.32%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
199.35%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21/03/19
|
18/03/20
|
17/03/21
|
18/03/22
|
23/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
55,675
|
53,574
|
55,621
|
32,961
|
15,607
|
10,610
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-59.81
x
|
21.72
x
|
-905.3
x
|
9.856
x
|
0.8472
x
|
7.754
x
|
Free Cash Flow
1 |
-7,302
|
2,934
|
-11,563
|
-781
|
13,460
|
5,724
|
ROE (net income / shareholders' equity)
|
-11.3%
|
-17%
|
-30.7%
|
-9.61%
|
6.08%
|
-16.3%
|
ROA (Net income/ Total Assets)
|
-1.91%
|
-1.27%
|
-2.02%
|
-1.06%
|
4.11%
|
-1.62%
|
Assets
1 |
474,677
|
1,078,057
|
963,248
|
688,325
|
164,180
|
959,373
|
Book Value Per Share
2 |
4,563
|
3,926
|
3,674
|
3,641
|
4,014
|
3,156
|
Cash Flow per Share
2 |
243.0
|
802.0
|
586.0
|
318.0
|
1,002
|
1,030
|
Capex
1 |
1,498
|
2,215
|
1,924
|
1,674
|
3,173
|
1,885
|
Capex / Sales
|
1.08%
|
1.63%
|
1.48%
|
1.19%
|
1.92%
|
1.37%
|
Announcement Date
|
21/03/19
|
18/03/20
|
17/03/21
|
18/03/22
|
23/03/23
|
21/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -22.90% | 145M | | -14.44% | 77.05B | | +14.56% | 8.44B | | +25.88% | 3.73B | | +18.24% | 1.69B | | -8.82% | 1.52B | | -22.51% | 1.3B | | -3.32% | 1.27B | | -10.11% | 1.18B | | +4.27% | 1.09B |
Veterinary Drugs
|